GuruFocus - On August 26, 2024, Stephen Betz, Chief Scientific Officer of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX), sold 3,000 shares of the company at a price of $53.19 per share. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 69,611 shares of Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Over the past year, Stephen Betz has sold a total of 39,000 shares of Crinetics Pharmaceuticals Inc and has not made any purchases of the stock. The company's insider transaction history reveals a pattern of 36 insider sales and no insider buys over the last year.
The shares of Crinetics Pharmaceuticals Inc were trading at $53.19 on the day of the transaction, giving the company a market cap of approximately $4.35 billion. This valuation reflects the stock's current GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow.
This insider sale may be of interest to investors tracking insider behaviors as an indicator of company performance and valuation trends.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This content was originally published on Gurufocus.com
